Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week
Key Insights
關鍵見解
- Given the large stake in the stock by institutions, Ventyx Biosciences' stock price might be vulnerable to their trading decisions
- 53% of the business is held by the top 9 shareholders
- Insiders have bought recently
- 鑑於機構持有該股的大量股份,Ventyx Biosciences的股價可能容易受到其交易決策的影響
- 53% 的業務由前 9 名股東持有
- 內部人士最近買了
To get a sense of who is truly in control of Ventyx Biosciences, Inc. (NASDAQ:VTYX), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 59% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要了解誰真正控制了Ventyx Biosciences, Inc.(納斯達克股票代碼:VTYX),了解業務的所有權結構非常重要。我們可以看到,機構擁有該公司的大部分股份,所有權爲59%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。
And last week, institutional investors ended up benefitting the most after the company hit US$146m in market cap. One-year return to shareholders is currently 10% and last week's gain was the icing on the cake.
上週,在該公司的市值達到1.46億美元之後,機構投資者最終受益最大。目前,一年股東回報率爲10%,上週的漲幅錦上添花。
Let's delve deeper into each type of owner of Ventyx Biosciences, beginning with the chart below.
讓我們從下圖開始,深入研究Ventyx Biosciences的每種所有者。
What Does The Institutional Ownership Tell Us About Ventyx Biosciences?
關於Ventyx Biosciences,機構所有權告訴我們什麼?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。
As you can see, institutional investors have a fair amount of stake in Ventyx Biosciences. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Ventyx Biosciences' earnings history below. Of course, the future is what really matters.
如你所見,機構投資者在Ventyx Biosciences中擁有相當數量的股份。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。如果多家機構同時改變對股票的看法,你可能會看到股價快速下跌。因此,值得在下面查看Ventyx Biosciences的收益記錄。當然,未來才是真正重要的。
Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 16% of Ventyx Biosciences shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is New Science Ventures, LLC, with ownership of 10%. In comparison, the second and third largest shareholders hold about 9.5% and 6.9% of the stock. Furthermore, CEO Raju Mohan is the owner of 2.4% of the company's shares.
投資者應注意,機構實際上擁有公司一半以上的股份,因此它們可以共同行使巨大的權力。看來Ventyx Biosciences有16%的股票由對沖基金控制。這引起了我的注意,因爲對沖基金有時會試圖影響管理層,或者帶來能夠爲股東創造短期價值的變革。該公司的最大股東是新科學風險投資有限責任公司,所有權爲10%。相比之下,第二和第三大股東持有約9.5%和6.9%的股份。此外,首席執行官拉朱·莫漢是該公司2.4%股份的所有者。
We did some more digging and found that 9 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
我們進行了更多挖掘,發現9名最大股東約佔註冊總額的53%,這意味着除了較大的股東外,還有一些較小的股東,從而在一定程度上平衡了彼此的利益。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。有相當數量的分析師在報道該股,因此了解他們對未來的總體看法可能很有用。
Insider Ownership Of Ventyx Biosciences
Ventyx Biosciences 的內部所有權
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。
We can see that insiders own shares in Ventyx Biosciences, Inc.. It has a market capitalization of just US$146m, and insiders have US$4.7m worth of shares, in their own names. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.
我們可以看到內部人士擁有Ventyx Biosciences, Inc.的股份。它的市值僅爲1.46億美元,內部人士以自己的名義持有價值470萬美元的股票。很高興看到內部人士進行一些投資,但我們通常希望看到更多的內部持有量。可能值得檢查一下這些內部人士是否在買入。
General Public Ownership
一般公有制
With a 12% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Ventyx Biosciences. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Ventyx Biosciences擁有12%的所有權,主要由個人投資者組成的公衆對Ventyx Biosciences有一定程度的影響力。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
Private Equity Ownership
私募股權所有權
With an ownership of 10%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
私募股權公司擁有10%的所有權,可以在制定以價值創造爲重點的公司戰略方面發揮作用。有些人可能會喜歡這樣,因爲私募股權有時是追究管理層責任的激進分子。但是其他時候,私募股權在公司上市後正在售罄。
Next Steps:
後續步驟:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 4 warning signs for Ventyx Biosciences (1 shouldn't be ignored!) that you should be aware of before investing here.
儘管值得考慮擁有公司的不同群體,但還有其他因素更爲重要。例如,我們發現了 Ventyx Biosciences 的 4 個警告信號(1 個不容忽視!)在這裏投資之前,您應該注意這一點。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。